Current therapeutic options for metastatic hormone receptor–positive HER2 negative breast cancer patients without visceral crisis include selective ER modulators (SERMs), selective ER degraders (SERDs), aromatase inhibitors (AIs), and cyclin-dependent kinase (CDK) 4/6 inhibitors [3]. This evidence concerns the gene NR4A1 and breast cancer.